Shopping Cart
Remove All
Your shopping cart is currently empty
AVE3085 is an endothelial nitric oxide synthase enhancer that restores endothelial function and reduces blood pressure in spontaneously hypertensive rats, used in cardiovascular disease research.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $61 | - | In Stock | |
| 5 mg | $147 | - | In Stock | |
| 10 mg | $239 | - | In Stock | |
| 25 mg | $455 | - | In Stock | |
| 50 mg | $762 | - | In Stock | |
| 100 mg | $1,190 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | - | In Stock |
| Description | AVE3085 is an endothelial nitric oxide synthase enhancer that restores endothelial function and reduces blood pressure in spontaneously hypertensive rats, used in cardiovascular disease research. |
| In vitro | AVE3085 (10 μM) at 37°C for 60 min significantly increased the expression of eNOS and p-eNOS (Ser1177) in coronary endothelial cells. [3] |
| In vivo | Treatment of spontaneously hypertensive rats (SHR) with AVE3085 (10 mg/kg/day, oral) for 4 weeks greatly improved endothelum-dependent relaxation of the aorta in SHR and reduced blood pressure in SHR. [1] AVE3085 (10 mg/kg/day, taken orally) improves endothelial dysfunction in db/db mice, thereby reducing oxidative stress in blood vessel walls. [2] |
| Synonyms | AVE-3085 |
| Molecular Weight | 317.29 |
| Formula | C17H13F2NO3 |
| Cas No. | 450348-85-3 |
| Smiles | O=C(NC1CC=2C=CC=CC2C1)C3=CC=C4OC(F)(F)OC4=C3 |
| Relative Density. | 1.43 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 200 mg/mL (630.34 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (10.4 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.